British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

The FTSE 100 index is set to remain under pressure, having fallen by 0.8% in yesterday’s session. Futures trading is pointing ...

Thousands of apartments have been added — and hundreds taken away — from Greater Philadelphia's pipeline in recent weeks, ...

Despite pressure on consumer spending, consumers prioritise trusted brands for their health-related needs and Haleon is a ...

Pfizer's Q3 earnings soar on COVID revenue but stock dips as market doubts long-term growth. See why I think that 2025 will not be a strong year for PFE stock.

In an era where ‘side hustle’ has amassed over 2.8 billion views on TikTok, some seasoned business leaders argue that the ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

A little over six months into her appointment, Chimeric’s youthful chief operating officer – and in effect CEO – Dr Rebecca ...

Every time the name changed ... s life science future. Those GSK lab doors rattling shut are also going to open some new ones. New businesses. New opportunities. So let’s raise a glass, even if you ...